Anorexia Nervosa
- 1 February 1986
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 43 (2) , 177-181
- https://doi.org/10.1001/archpsyc.1986.01800020087011
Abstract
• Patients with anorexia nervosa have concurrent problems of emaciation and depression. Therefore, treatment with medications affecting both weight gain and depression seemed reasonable. Seventy-two anorectic patients were randomly assigned in a double-blind study to receive cyproheptadine hydrochloride, a weight-inducing drug, amitriptyline hydrochloride, a tricyclic antidepressant, or placebo. Overall, cyproheptadine had a marginal effect on decreasing the number of days necessary to achieve a normal weight. There was a differential drug effect present in the bulimic subgroups of the anorectic patients: cyproheptadine significantly increased treatment efficiency for the nonbulimic patients and significantly impaired treatment efficiency for the bulimic patients when compared with the amitriptyline- and placebo-treated groups. The differential cyproheptadine effect on the anorectic bulimic subgroups is the first pharmacologic evidence of the validity of these subgroups. Cyproheptadine had an antidepressant effect demonstrated by a significant decrease in the Hamilton depression ratings.This publication has 3 references indexed in Scilit:
- The Heterogeneity of Anorexia NervosaArchives of General Psychiatry, 1980
- Cyproheptadine Hydrochloride (Periactin) and Anorexia Nervosa: A Case ReportThe British Journal of Psychiatry, 1970
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961